- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00085761
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
March 4, 2008 updated by: NeurogesX
An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 34239
- NeurogesX Investigational Site
-
-
Virginia
-
Annandale, Virginia, United States, 22003
- NeurogesX Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Eligibility Criteria:
- Must have had HIV-associated neuropathy for at least 2 months, with moderate to severe pain in both feet.
- Must not have significant pain in feet due to other causes (for example, arthritis).
- Must have intact skin at the treatment area.
- Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks).
- Must not use topical pain medications for HIV-associated neuropathy.
- Must be able to comply with study requirements such as completing daily pain diary and attending study visits.
- Must be at least 18 years old, not pregnant, and be able to take care of self independently, with only occasional assistance if needed.
- No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
- No history or current problem with substance abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 14, 2004
First Submitted That Met QC Criteria
June 16, 2004
First Posted (Estimate)
June 17, 2004
Study Record Updates
Last Update Posted (Estimate)
March 6, 2008
Last Update Submitted That Met QC Criteria
March 4, 2008
Last Verified
March 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neuromuscular Diseases
- HIV Infections
- Peripheral Nervous System Diseases
- Nervous System Diseases
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Dermatologic Agents
- Antipruritics
- Capsaicin
Other Study ID Numbers
- C112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Capsaicin Dermal Patch
-
NeurogesXCompletedPain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | ShinglesUnited States
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System DiseasesUnited States
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster
-
NeurogesXUnknownHIV InfectionsUnited States
-
NeurogesXTerminatedHIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Polyneuropathies
-
NeurogesXCompletedPain | Peripheral Nervous System Diseases | Neuralgia | Herpes ZosterUnited States
-
NeurogesXCompletedHIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | PolyneuropathiesUnited States
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases
-
The University of Texas Health Science Center at...CompletedNeuropathic Pain | Spinal Cord InjuriesUnited States
-
Samyang Biopharmaceuticals CorporationCompletedPostherpetic Neuralgia | Peripheral Nerve InjuryKorea, Republic of